Search the Newsreel

GeoVax Labs (GOVX) holders report 1.59% stake tied to 118,715 warrants

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri collectively reported beneficial ownership of 118,715 shares of GeoVax Labs (GOVX) common stock through warrants. This represents a 1.59% stake based on 7,369,243 shares outstanding as of July …

Is Planet Labs The Cheapest Stock In The Space Economy?

Key Points Planet Labs’ stock has plunged more than 50% from its all-time high. It's cheaper than its peers, but investors shouldn’t ignore the red flags.10 stocks we like better than Planet Labs PBC › Planet Labs(NYSE: PL), a developer of satellite constellations, went …

Earnings call transcript: MediPharm Labs posts first profit since 2019 in Q2 2026

7,574 Shares in Astera Labs, Inc. $ALAB Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. has acquired 7,574 shares of Astera Labs, Inc. (NASDAQ:ALAB) for approximately $3.66 million, marking a new position for the institutional investor. This move comes amidst Astera Labs' strong quarterly performance, with revenue increasing by 104.5% year-over-year and EPS beating analyst …

GeoVax Labs, Inc. (GOVX) holders cap ownership at 4.99% with warrants

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively reported a 4.99% beneficial ownership in GeoVax Labs, Inc. (GOVX) as of June 2026, totaling 273,657 shares derived from exercisable warrants. This stake is capped at 4.99% due to blocker provisions in additional …

Q2 2026 Medipharm Labs Corp Earnings Call Transcript

Innovana Thinklabs Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

GOVX: GEO-MVA targets a $1.3B vaccine market gap with expedited approval and scalable U.S. supply

GeoVax Labs, Inc. (GOVX) aims to disrupt the global MVA vaccine market with its GEO-MVA program, addressing a $1.3 billion demand through a fast-tracked regulatory process and scalable U.S. manufacturing. Additionally, the company is advancing Gedeptin® as a novel therapy for solid tumors, supported …

Why Medipharm Labs Corp stock surged yesterday

Citigroup Upgrades Establishment Labs to Buy From Neutral, Price Target is $92

Citigroup has upgraded its rating for Establishment Labs Holdings Inc. to 'Buy' from 'Neutral', setting a new price target of $92. This upgrade follows the company's recent Q2 2026 earnings report, where it exceeded revenue estimates and raised its full-year 2026 earnings guidance. Establishment …

Q3 EPS Estimates for Shattuck Labs Raised by HC Wainwright

HC Wainwright has raised its Q3 2026 EPS estimate for Shattuck Labs (NASDAQ:STTK) to a loss of $0.09 per share, an improvement from the previous estimate of a $0.21 loss. The firm maintained a "Buy" rating and a $14 price target, while the overall …

Australian Clinical Labs Limited (ASX:ACL) Share Price Rises 1.72% as Stock Trades Within Daily Range

Amagi Media Labs Hits Record High on Strong Q1 Results

Handelsbanken Fonder AB Raises Holdings in Astera Labs, Inc. $ALAB

Amagi Media Labs consolidated net profit rises 760.66% in the June 2026 quarter

Proto Labs, Inc. $PRLB Position Raised by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Proto Labs, Inc. (NYSE:PRLB) by 98.9% in the first quarter, now owning 27,716 shares valued at $1.58 million. This comes as Proto Labs reported strong quarterly earnings, beating analyst estimates with an EPS of $0.60 …

Amagi Media Labs surges after Q1 PAT jumps over 8-fold to Rs 34 cr

214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ:BIOA), purchasing 214,546 shares valued at approximately $3.75 million, representing a 0.48% stake in the company. Other institutional investors like Geode Capital and Marshall Wace also increased their holdings. Despite reporting a …

Astera Labs, Inc. (NASDAQ:ALAB) Given Average Recommendation of "Moderate Buy" by Analysts

Analysts have issued a "Moderate Buy" rating for Astera Labs (NASDAQ:ALAB), with 13 buy recommendations and 10 hold ratings, and an average 12-month price target of $325.25. The company demonstrated strong operating momentum, with revenue up 104.5% year-over-year and EPS exceeding estimates, driven by …

Amagi Media Labs releases Q1 FY27 earnings call audio recording

Amagi Media Labs Q1FY27 net profit up 756%, EBITDA turns positive

VivoSim: Fiscal Q1 Earnings Snapshot

VivoSim Labs, Inc. (VIVS) reported a fiscal first-quarter loss of $1.3 million, or 25 cents per share. The San Diego-based development-stage company, which focuses on functional human tissue for research, posted revenue of $18,000 for the period.

Astera Labs Inc Stock (ALAB) Moved Up by 6.11% on Aug 12: Key Drivers Unveiled

Astera Labs Inc (ALAB) saw its stock price increase by 6.11% on August 12, driven by strong quarterly financial results that surpassed expectations and robust demand for its semiconductor connectivity solutions in AI infrastructure. Analyst upgrades and positive market sentiment surrounding AI deployment also …

Astera Labs (NASDAQ:ALAB) Shares Gap Up - Should You Buy?

Astera Labs (NASDAQ:ALAB) shares gapped up by 6.6% to $334.49, driven by optimism for AI connectivity products and strong financial results including 104.5% year-over-year revenue growth. Northland Securities significantly raised its earnings forecasts for the company, while AMD's Helios AI systems are anticipated to …

Why Thinkific Labs Inc stock is sliding today

Astera Labs: The AI Fabric Inflection Is Arriving Faster Than Expected (NASDAQ:ALAB)

ALAB Benefits From PCIe Demand: Can It Stay Ahead of Its Competitors?

Astera Labs (ALAB) is experiencing significant growth due to high demand for PCIe solutions, especially in AI infrastructure, with record revenues in Q2 2026 and strong projections for Q3. The company's diverse product portfolio and focus on next-generation technologies like PCIe 6, UALink, and …

Proto Labs (PRLB) Upgraded to Strong Buy: Here's Why

Proto Labs (PRLB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The …

Astera Labs' (NASDAQ:ALAB) Promising Earnings May Rest On Soft Foundations

Proto Labs Inc stock hits 52-week high at 92.0 USD

Proto Labs Inc. (PRLB) shares have reached a new 52-week high of $92.00, driven by an impressive 90% total return over the past year and nearly 79% year-to-date. This growth follows strong Q2 results, exceeding analyst expectations with record revenue and adjusted earnings, and …

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright has lowered its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18, while maintaining a Buy rating, following the company's Q2 2026 financial results and an expanded Phase 2b trial for its lead asset, SL-325. Despite the price target cut, the …

Needham Maintains Shattuck Labs(STTK.US) With Buy Rating, Maintains Target Price $17

Needham has reiterated its Buy rating for Shattuck Labs (STTK.US) and maintained its price target at $17. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and potential.

BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts

BioAge Labs, Inc. (NASDAQ:BIOA) has received a "Moderate Buy" consensus rating from analysts, with six out of seven recommending a buy and one a sell. The average 12-month price target is $36.57, though recent targets vary from $21 to $40. The company reported a …

Tema ETFs LLC Has $52.71 Million Stake in Planet Labs PBC $PL

Several Insiders Invested In Shattuck Labs Flagging Positive News

Several insiders at Shattuck Labs (NASDAQ:STTK) have recently bought shares, with one independent director purchasing US$250k worth. While this buying activity occurred at a price below current market value, it suggests insiders view the company's prospects positively. Despite a recent loss, the substantial insider …

Australian Clinical Labs (ASX:ACL) Value Case Builds as Healthcare Stock Reprices